Contraception-Pipeline Review, H2 2015

Contraception-Pipeline Review, H2 2015

  • Products Id :- GMDHC6941IDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Contraception-Pipeline Review, H2 2015


Global Markets Direct's, 'Contraception-Pipeline Review, H2 2015', provides an overview of the Contraception's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Contraception

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Contraception

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Contraception Overview 9

Therapeutics Development 10

Pipeline Products for Contraception-Overview 10

Pipeline Products for Contraception-Comparative Analysis 11

Contraception-Therapeutics under Development by Companies 12

Contraception-Therapeutics under Investigation by Universities/Institutes 13

Contraception-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Contraception-Products under Development by Companies 17

Contraception-Products under Investigation by Universities/Institutes 18

Contraception-Companies Involved in Therapeutics Development 19

Agile Therapeutics, Inc. 19

Allergan Plc 20

ANI Pharmaceuticals, Inc. 21

Antares Pharma, Inc. 22

Evofem, Inc. 23

Hydra Biosciences, Inc. 24

Ligand Pharmaceuticals, Inc. 25

Orbis Biosciences, Inc. 26

Pantarhei Bioscience BV 27

Spermatech AS 28

Contraception-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

(ethinyl estradiol + levonorgestrel)-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

(nestorone + estradiol acetate)-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

(prasterone + estradiol + progesterone)-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

AG-200 ER-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

AG-200 SP-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Amphora-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drug for Male Contraception-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

EP-007-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

esterol-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

etonogestrel-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

EVE-106-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

levonorgestrel-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

LJ-102-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Monoclonal Antibody Conjugates for Contraception-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

norethindrone-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

S-003296-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

S-0101255-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecule 1 for Fertility Control-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecule 2 for Fertility Control-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecule to Modulate Progesterone Receptor for Fertility Control-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules to Block CatSper1 Ion Channel for Contraception-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Synthetic Peptides for Contraception-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

tanaproget-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Contraception-Recent Pipeline Updates 67

Contraception-Dormant Projects 72

Contraception-Dormant Projects 72

Contraception-Discontinued Products 73

Contraception-Product Development Milestones 74

Featured News & Press Releases 74

Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive 74

Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive 74

Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 74

Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 75

Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 75

Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 75

Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 76

Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 76

Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 77

Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 77

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Contraception, H2 2015 10

Number of Products under Development for Contraception-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Investigation by Universities/Institutes, H2 2015 18

Contraception-Pipeline by Agile Therapeutics, Inc., H2 2015 19

Contraception-Pipeline by Allergan Plc, H2 2015 20

Contraception-Pipeline by ANI Pharmaceuticals, Inc., H2 2015 21

Contraception-Pipeline by Antares Pharma, Inc., H2 2015 22

Contraception-Pipeline by Evofem, Inc., H2 2015 23

Contraception-Pipeline by Hydra Biosciences, Inc., H2 2015 24

Contraception-Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 25

Contraception-Pipeline by Orbis Biosciences, Inc., H2 2015 26

Contraception-Pipeline by Pantarhei Bioscience BV, H2 2015 27

Contraception-Pipeline by Spermatech AS, H2 2015 28

Assessment by Monotherapy Products, H2 2015 29

Assessment by Combination Products, H2 2015 30

Number of Products by Stage and Target, H2 2015 32

Number of Products by Stage and Mechanism of Action, H2 2015 34

Number of Products by Stage and Route of Administration, H2 2015 36

Number of Products by Stage and Molecule Type, H2 2015 38

Contraception Therapeutics-Recent Pipeline Updates, H2 2015 67

Contraception-Dormant Projects, H2 2015 72

Contraception-Discontinued Products, H2 2015 73

List of Figures

Number of Products under Development for Contraception, H2 2015 10

Number of Products under Development for Contraception-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 29

Assessment by Combination Products, H2 2015 30

Number of Products by Targets, H2 2015 31

Number of Products by Stage and Targets, H2 2015 31

Number of Products by Mechanism of Actions, H2 2015 33

Number of Products by Stage and Mechanism of Actions, H2 2015 33

Number of Products by Routes of Administration, H2 2015 35

Number of Products by Stage and Routes of Administration, H2 2015 35

Number of Products by Molecule Types, H2 2015 37

Number of Products by Stage and Molecule Types, H2 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Agile Therapeutics, Inc.

Allergan Plc

ANI Pharmaceuticals, Inc.

Antares Pharma, Inc.

Evofem, Inc.

Hydra Biosciences, Inc.

Ligand Pharmaceuticals, Inc.

Orbis Biosciences, Inc.

Pantarhei Bioscience BV

Spermatech AS

Contraception Therapeutic Products under Development, Key Players in Contraception Therapeutics, Contraception Pipeline Overview, Contraception Pipeline, Contraception Pipeline Assessment

select a license

Single User License
USD 2000 INR 145040
Site License
USD 4000 INR 290080
Corporate User License
USD 6000 INR 435120



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]